{
  "extraction_metadata": {
    "timestamp": "2025-09-29T13:06:42.136270",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "total_picos": 38
  },
  "picos_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "PICOs": [
        {
          "Population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "Child-Pugh A patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE + sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "hepatocellular carcinoma patients",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "Patients with HCC. Patients were not suitable candidates for surgical resection; participants were 18 years of age or older.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 6111
    },
    "CZ": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "CZ",
      "PICOs": [],
      "ChunksUsed": 1,
      "ContextTokens": 202
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "Child-Pugh A patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "Child-Pugh A patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE + sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "arterial embolization",
          "Outcomes": ""
        },
        {
          "Population": "hepatocellular carcinoma patients",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "patients with HCC. Patients were not suitable candidates for surgical resection; participants were 18 years of age or older.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "Participants with intermediate-stage hepatocellular carcinoma (BCLC stage B) irrespective of the presence of cirrhosis, size and number of the tumours (provided they met the criteria of intermediate-stage hepatocellular carcinoma), presence or absence of portal hypertension, aetiology of hepatocellular carcinoma, and the future remnant liver volume. Randomised clinical trials in which participants had undergone liver transplantation previously were excluded.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "supportive care",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 6111
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "treatment naive adult (aged ≥18 years) patients with advanced, unresectable or metastatic hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "Adult patients with advanced HCC and adult patients with inoperable HCC.",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 7016
    },
    "EN": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EN",
      "PICOs": [
        {
          "Population": "adults with advanced or unresectable HCC with Child-Pugh grade A liver impairment and an ECOG performance status of 0 or 1, who have not had previous systemic treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "adults with advanced or unresectable HCC with Child-Pugh grade A liver impairment and an ECOG performance status of 0 or 1, who have not had previous systemic treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 5552
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "PICOs": [
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "Patients aged 18 years or older and diagnosed with locally advanced or metastatic and/ or unresectable HCC with histological/ cytological confirmation or clinical features consistent with the American Association for the Study of the Liver (AASLD) criteria in cirrhotic patients",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy, with hepatic function (Child-Pugh carcinomas: a phase III randomised, double-blind, stage A), an ECOG score of 0 or 1, in the absence of a placebo-controlled trial",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 29,
      "ContextTokens": 7389
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma (HCC) (stage BCLC B or C) who have not received prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable liver cell carcinomas",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 7346
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "PICOs": [
        {
          "Population": "patients with advanced hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "patients with hepatocellular carcinoma for whom intentional curative treatment or (continuation of) locoregional or local palliative treatment is not possible or considered medically unnecessary (advanced hepatocellulose cancer)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best care regimen available",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 4583
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "PICOs": [],
      "ChunksUsed": 30,
      "ContextTokens": 6985
    },
    "PT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PT",
      "PICOs": [
        {
          "Population": "adult patients with advanced or non-resectable hepatocellular carcinoma (HCC) and who have not received any previous systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 22,
      "ContextTokens": 3364
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Tecentriq (atezolizumab) plus bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Lenvima (lenvatinib)",
          "Outcomes": ""
        },
        {
          "Population": "patients with HCC with non-viral etiologies",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Tecentriq plus bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients for whom treatment with atezoumab plus bevacizumab is inappropriate",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients for whom treatment with atezoumab plus bevacizumab is inappropriate",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 30,
      "ContextTokens": 6717
    }
  }
}